<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04566978</url>
  </required_header>
  <id_info>
    <org_study_id>19-479</org_study_id>
    <nct_id>NCT04566978</nct_id>
  </id_info>
  <brief_title>89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)</brief_title>
  <official_title>A Pilot Study of 89Zr-DFO-REGN3767 Anti LAG-3 Antibody Positron Emission Tomography in Patients With Relapsed/Refractory DLBCL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purposes of this study include:&#xD;
&#xD;
      Looking at the way the body absorbs, distributes, and gets rid of 89Zr-DFO-REGN3767&#xD;
&#xD;
      Finding the best dose amount of 89Zr-DFO-REGN3767&#xD;
&#xD;
      Finding the best time for PET scanning after injection of 89Zr-DFO-REGN3767&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2020</start_date>
  <completion_date type="Anticipated">September 11, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 11, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biodistribution of 89Zr-DFO-REGN3767</measure>
    <time_frame>2 years</time_frame>
    <description>A PET/CT scan extending from top of skull to feet will be performed to determine the biodistribution of 89Zr-DFO-REGN3767</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Optimal 89Zr-DFO-REGN3767 mass dose for tumor targeting</measure>
    <time_frame>2 years</time_frame>
    <description>Determine the optimal 89Zr-DFO-REGN3767 mass dose for tumor targeting</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Optimal time for imaging and tumor uptake post 89Zr-DFO-REGN3767 administration</measure>
    <time_frame>2 years</time_frame>
    <description>Determine the optimal time for imaging and tumor uptake post 89Zr-DFO-REGN3767 administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor lesion uptake of 89Zr-DFO-REGN3767 and correlate with LAG-3 expression by IHC</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluate tumor lesion uptake of 89Zr-DFO-REGN3767 and correlate with LAG-3 expression by IHC in tumors will be compared descriptively with other biomarkers of tumor immune environment characterized in biopsies, such as quantitation of IHC score (LAG-3 and / or other immune cell markers), or other biomarker measures.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Large B-cell Lymphoma</condition>
  <condition>DLBCL</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 3 participants will be enrolled to receive a single dose of 89Zr-DFO-REGN3767 (total 2mg antibody mass). Participant to undergo 3 PET/CT scans and concurrent blood draws for PK</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 3 participants will be enrolled to receive a total 5mg of 89Zr-DFO-REGN3767 (+REGN3767) total antibody mass for PK and serial imaging with 3 PET/CT scans</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 3 participants will be enrolled to receive a total 10mg of 89Zr-DFO-REGN3767 (+REGN3767) total antibody mass for PK and serial imaging with 3 PET/CT scans</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 3 participants will be enrolled to receive a total 20mg of 89Zr-DFO-REGN3767 (+REGN3767) total antibody mass for PK and serial imaging with 3 PET/CT scans</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>89Zr-DFO-REGN3767</intervention_name>
    <description>89Zr-DFO-REGN3767 is comprised of the anti-LAG-3 antibody, REGN3767 labeled with the positron-emitter zirconium-89 (89Zr) through the chelator-linker DFO. REGN3767 is an investigational monoclonal antibody that target LAG-3 receptors.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PET/CT</intervention_name>
    <description>A PET/CT scan extending from top of skull to feet will be performed to determine the biodistribution.&#xD;
Part A patients will be imaged at three time points post-injection to allow for selection of optimal imaging time and dosimetry determination. For these patients, top of skull to feet scans will be acquired:&#xD;
Within one to four hours following injection of tracer on Day 1&#xD;
24-72 hours post-injection (Day 2-4)&#xD;
20-168 hours post-injection (once during days 5-7)</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A patient must be eligible for DLBCL expansion cohort 9 in study 17-421 and, in addition,&#xD;
        meet the following criteria to be eligible for inclusion in the study:&#xD;
&#xD;
          -  Measurable disease by Lugano criteria, with at least one lesion outside of the liver&#xD;
&#xD;
          -  Patients must have eGFR &gt;50 mL/min/1.73m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A patient must be eligible for DLBCL expansion cohort 9 in study 17-421 and, in addition, a&#xD;
        patient who meets any of the following criteria will be excluded from the study:&#xD;
&#xD;
          -  Patients who have permanently discontinued anti-cancer immune modulating therapies due&#xD;
             to drug-related toxicity.&#xD;
&#xD;
          -  Has not yet recovered (i.e. ≤ Grade 1 or baseline) from any acute toxicities from&#xD;
             prior anticancer therapy except for laboratory changes as described in inclusion&#xD;
             criteria in study 17-421, except as noted. NOTE: Patients with chronic or stable&#xD;
             toxicity following approved therapy, such as mild persistent neuropathy, are allowed.&#xD;
&#xD;
          -  Has received radiation therapy within 14 days of first administration of study drug or&#xD;
             has not recovered (i.e. ≤ Grade 1 or baseline) from adverse events, except for&#xD;
             laboratory changes as described in inclusion criteria, except as noted. NOTE: Patients&#xD;
             with chronic or stable toxicity, such as mild persistent neuropathy, are allowed.&#xD;
&#xD;
          -  Women who are pregnant, breastfeeding *Postmenopausal women must be amenorrhoeic for&#xD;
             at least 12 months in order not to be considered of childbearing potential. Pregnancy&#xD;
             testing and contraception are not required for women with documented hysterectomy or&#xD;
             tubal ligation. Pregnancy testing and screening will be performed per MSK and&#xD;
             Department of Radiology standard pregnancy screening guidelines.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neeta Pandi-Taskar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Neeta Pandi-Taskar, MD</last_name>
    <phone>212-639-3046</phone>
    <email>pandit-n@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lia Palomba, MD</last_name>
    <phone>646-608-3711</phone>
    <email>palombam@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neeta Pandit-Taskar, MD</last_name>
      <phone>212-639-3046</phone>
    </contact>
    <contact_backup>
      <last_name>Lia E. Lalomba, MD</last_name>
      <phone>646-608-3711</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2020</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Large B-cell Lymphoma</keyword>
  <keyword>DLBCL</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <keyword>19-479</keyword>
  <keyword>89Zr-DFO-REGN3767</keyword>
  <keyword>anti LAG-3 antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

